We are live on ! Find out more
ODT

Odonate Therapeutics, Inc. Common Stock

Delisted

ODT was delisted on the 14th of January, 2022.

83 hedge funds and large institutions have $111M invested in Odonate Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 23

12% less funds holding

Funds holding: 9483 (-11)

18% less call options, than puts

Call options by funds: $906K | Put options by funds: $1.1M

31% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 35

75% less funds holding in top 10

Funds holding in top 10: 41 (-3)

85% less capital invested

Capital invested by funds: $721M → $111M (-$611M)

Holders
83
Holders Change
-11
Holders Change %
-11.7%
% of All Funds
1.46%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
24
Increased
25
Reduced
23
Closed
35
Calls
$906K
Puts
$1.1M
Net Calls
-$195K
Net Calls Change
-$1.04M

ODT Hedge Fund Activity: Q1 2021 in Review

83 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q1 2021, worth a combined $111M — down 85% from $721M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ODT and 24 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 25 added.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $25.3M. The largest seller was Wellington Management Group, exiting entirely with an estimated $72.4M sold.

  • 83 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q1 2021, down from 94 in Q4 2020.
  • Funds reported $111M of Odonate Therapeutics, Inc. Common Stock stock for Q1 2021, down 85% quarter-over-quarter.
  • 24 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q1 2021 and 35 closed out, a net change of -11 holders.
  • The largest Odonate Therapeutics, Inc. Common Stock buyer in Q1 2021 was Ikarian Capital, an estimated $25.3M added.
  • The largest Odonate Therapeutics, Inc. Common Stock seller in Q1 2021 was Wellington Management Group, an estimated $72.4M sold.

Based on aggregated 13F filings for Q1 2021.